Liang et al. [31] evaluated 76 NPC cases with concurrent chemoradiotherapy, and demonstrated that the response rate of patients with positive ERCC1 expression is significantly lower than that of the negative expression group (75% vs 97.7%, P = 0.008). The gene discussed is ERCC1; the disease is nasopharyngeal carcinoma.